Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [2] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [2] Product Development - Izicopan is being developed for the treatment of various inflammatory diseases, including hidradenitis suppurativa [2] - The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [2] Corporate Information - InflaRx was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [3] - InflaRx GmbH and InflaRx Pharmaceuticals Inc. are wholly owned subsidiaries of InflaRx N.V. [3] Upcoming Events - InflaRx will participate in the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, in New York, NY, where the company will hold one-on-one investor meetings [1]

Core Insights - InflaRx N.V. announced positive data from a Phase 3 study of vilobelimab for pyoderma gangrenosum, presented at the 2026 AAD Annual Meeting [1][2] Group 1: Study Results - The Phase 3 trial showed higher rates of complete remission (20.8% for vilobelimab vs. 5.1% for placebo) and target ulcer closure (20.8% vs. 16.7%) [4] - Over one-third of vilobelimab-treated patients achieved more than a 50% reduction in ulcer volume (36.4% vs. 16.7% for placebo) [4] - Vilobelimab treatment significantly reduced C5a levels by -76.6% compared to -13.5% with placebo [5] Group 2: Safety Profile - The treatment was generally well tolerated, with most adverse events being mild to moderate, and similar rates of serious adverse events (6.3% for vilobelimab vs. 4.5% for placebo) [5] Group 3: Future Development - InflaRx is prioritizing discussions with the FDA regarding izicopan for hidradenitis suppurativa while also planning to explore development options for vilobelimab in pyoderma gangrenosum, likely in collaboration with a partner [6] Group 4: Product Information - Vilobelimab is a first-in-class monoclonal antibody targeting complement factor C5a, designed to block its biological activity while preserving the innate immune system's defense mechanisms [7][9]

Core Insights - InflaRx N.V. announced an oral presentation of its Phase 3 study data for vilobelimab in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting [1][2] Company Overview - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary anti-C5a and anti-C5aR technologies to develop specific inhibitors targeting the complement activation factor C5a and its receptor C5aR [3] - The company's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [3] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [3] Upcoming Presentation Details - The oral presentation titled "Vilobelimab Treatment for Ulcerative Pyoderma Gangrenosum: Results from a Multicenter, Randomized, Placebo Controlled Phase 3 Trial" will be presented by Dr. Benjamin Kaffenberger on March 28, 2026, from 2:24 to 2:36 PM MT at the Bellco Theatre 3 [2]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [2] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [2] Product Development - Izicopan is being developed for the treatment of several inflammatory diseases, including hidradenitis suppurativa [2] - The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [2] Financial Information - InflaRx will publish its financial and operating results for the fourth quarter and full year 2025 on March 19, 2026, before the market opens [1]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [3] Product Development - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor of C5a-induced signaling, which has shown promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies [2] - The company is developing izicopan for the treatment of several inflammatory diseases, including hidradenitis suppurativa [2] - InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies [2] Upcoming Events - InflaRx will participate in the Leerink Partners Global Healthcare Conference from March 8 to 11, 2026, in Miami, FL, with a fireside chat scheduled for March 9 at 9:20 AM ET [1]

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Focus**: Biopharmaceutical company specializing in anti-C5a and C5a inhibitors for inflammatory diseases, including hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) [1][2] Core Points and Arguments Drug Development - **Izicopan**: A new oral inhibitor targeting C5a receptor 1, showing biologic-like efficacy in HS and CSU [3] - **Mechanism**: High potency on target engagement, with potential to be transformative in anti-inflammatory diseases [3] - **Pipeline**: Focused on broader inflammatory and immunology (I&I) space, with cash funding until mid-2027 [4] Competitive Positioning - **Best-in-Class Potential**: Studies indicate izicopan has a differentiated pharmacokinetic (PK) profile compared to marketed comparator avacopan, showing a 10x increase in area under the curve and a 3x higher peak [12][13] - **Safety Profile**: Izicopan has a 36-fold less engagement with CYP3A4/5, reducing the risk of liver toxicity [14] Clinical Trials and Results - **Phase II Study**: Completed in HS and CSU, showing significant reductions in abscess and inflammatory nodules, particularly in the high-dose group [19][24] - **Draining Tunnels**: 50% of patients in the high-dose group achieved zero draining tunnels by week four, indicating a meaningful early response [27] - **Pain Reduction**: Notable improvements in skin pain, with up to 75% of patients achieving a 30% improvement on the numeric rating scale [31] Market Opportunity - **ANCA-Associated Vasculitis**: Estimated market potential of over $1 billion, with current sales around $700 million globally [41] - **Differentiated Label Potential**: Opportunity to position izicopan as corticosteroid-sparing due to its unique mechanism and safety profile [42][43] Future Directions - **Regulatory Discussions**: Active discussions with the FDA regarding the development path for izicopan, with updates expected in spring [34] - **Chronic Spontaneous Urticaria**: Initial data shows promise, but HS remains the primary focus for development [36] Additional Important Content - **Patient Impact**: Emphasis on the significant social and physical burden of HS, highlighting the need for effective treatments [20] - **Comparative Analysis**: Izicopan's early efficacy in reducing draining tunnels and pain is positioned favorably against existing treatments [32][33] - **Long-term Efficacy**: Continued improvement in symptoms observed even after cessation of treatment, indicating potential for sustained benefits [30] This summary encapsulates the key points discussed during the conference call, focusing on InflaRx's strategic direction, drug development, clinical results, and market opportunities.

Summary of InflaRx Conference Call Company Overview - **Company**: InflaRx - **Industry**: Biotechnology - **Headquarters**: Germany and the U.S. - **IPO**: Listed on NASDAQ in 2017 - **Focus**: Development of drugs targeting terminal complement inhibition, specifically C5a and C5a receptor 1 Key Molecules - **Vilobelimab**: Antibody targeting C5a - **Izicopan**: Small molecule targeting C5a receptor 1 - Recently completed a positive proof of concept Phase 2a study [2][5] Differentiation of Izicopan - **Pharmacological Properties**: - Higher bioavailability and plasma levels compared to avacopan (Amgen's drug) - Faster onset of receptor inhibition, achieving peak levels in days versus avacopan's 13 weeks [5][6] - Significantly lower inhibition of CYP3A4, reducing potential drug-drug interactions [6] - **Safety Profile**: - No observed hepatotoxicity in 200 treated patients, contrasting with avacopan's reported issues [8][9] Market Opportunities - **Potential Market Impact**: If avacopan were withdrawn, InflaRx sees an opportunity to position izicopan favorably [13] - **Hidradenitis Suppurativa (HS)**: - Conducted a 28-day study showing promising results, including reduction of draining tunnels and pain [15][16] - Data compared favorably to existing treatments, indicating a potential best-in-class profile [27] Future Development Plans - **Next Steps**: - Planning a Phase 2B study, as the initial four-week trial does not suffice for pivotal trials [23] - Ongoing discussions with the FDA regarding dosing and trial design [21][25] - **Capital Markets Day**: Expected in spring, with disclosures on HS and other indications [24][36] Financial Position - **Cost Reduction**: Fixed costs reduced by approximately 30% due to the deprioritization of vilobelimab and related activities [33] Additional Indications - **Chronic Spontaneous Urticaria (CSU)**: Encouraging data suggests potential for further trials, contingent on resources [30][32] Conclusion InflaRx is positioned to leverage its differentiated drug izicopan in the competitive landscape of autoimmune diseases, particularly HS and potentially CSU, while maintaining a strong safety profile and reducing operational costs. The upcoming Capital Markets Day will provide further insights into their strategic direction and clinical development plans.

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [3] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [3] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [3] - The company is also developing vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability [3] Upcoming Events - InflaRx will participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026, with a fireside chat scheduled for February 11 at 11:30 AM ET [1] - The company will conduct one-on-one investor meetings on February 11 during the same summit [1] - InflaRx will also present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026, with a virtual presentation on February 25 at 8:40 AM ET [2] - One-on-one investor meetings will also be held on February 25 [2]

Core Insights - InflaRx N.V. has conducted multiple data analyses of its Phase 3 study for vilobelimab in pyoderma gangrenosum (PG), which was terminated due to futility as recommended by the Independent Data Monitoring Committee (IDMC) [1][7] Study Overview - The Phase 3 study enrolled 54 patients, with 30 completing 6 months of treatment. The primary endpoint of complete target ulcer closure showed a difference of 20.8% for vilobelimab versus 16.7% for placebo, though this was not statistically significant [3] - Key secondary endpoints indicated improvement for vilobelimab, including complete disease remission (20.8% vs. 5.6%, p=NS) and >50% reduction in target ulcer volume at week 26 (36.4% vs. 16.7%, p=NS) [3] Efficacy Signals - Post-hoc analyses revealed an overall treatment effect with vilobelimab, showing an average percent change in target ulcer volume of -45.4% (p=0.0428) from Weeks 2 to 26 [4] - Significant treatment differences were noted from Week 14 (-57.6%, p=0.0357) to Week 26 (-63.2%, p=0.0122) for vilobelimab compared to placebo [4] Tolerability and Safety - Vilobelimab was well tolerated, with treatment-emergent adverse events (TEAEs) mostly mild to moderate. Serious related TEAEs were reported at 6.3% in the vilobelimab arm and 4.5% in the placebo arm [3] Future Development Plans - InflaRx plans to meet with the FDA to discuss potential development pathways for vilobelimab in PG, which may involve collaboration with a partner [7][9] - The company is prioritizing the development of izicopan (INF904) and does not expect to allocate significant resources towards vilobelimab's development independently [9] Company Background - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary technologies to develop inhibitors of the complement activation factor C5a and its receptor [11] - Vilobelimab is a first-in-class monoclonal antibody targeting C5a, demonstrating disease-modifying clinical activity in various studies [10]

Core Viewpoint - InflaRx N.V. has received the international nonproprietary name "izicopan" for its C5aR inhibitor, previously known as INF904, from the World Health Organization, indicating a significant step in the drug's development process [1][2] Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically through its proprietary anti-C5a and anti-C5aR technologies [4] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, and is also advancing izicopan (INF904), an orally administered small molecule inhibitor [4][5] Product Details - Izicopan (INF904) is an orally administered small molecule that inhibits the C5a receptor, demonstrating anti-inflammatory effects in pre-clinical models and human studies [3] - Clinical trials have shown izicopan to be well tolerated, with no safety concerns reported across various dosing regimens, including single doses from 3 mg to 240 mg and multiple doses from 30 mg to 90 mg for 14 days [3] - Phase 2a data indicates that izicopan has the potential for best-in-class efficacy, achieving over 90% blockade of C5a-induced neutrophil activation during the dosing period [3] Clinical Efficacy - In patients with hidradenitis suppurativa, izicopan treatment resulted in significant reductions in abscesses and nodules, with improvements in pain scores and sustained responses observed four weeks post-treatment [3] - For chronic spontaneous urticaria, substantial reductions in the Urticaria Activity Score (UAS7) were noted, particularly among patients with severe disease, indicating improved disease control [3]